Zura Bio stock jumps on plans to raise $112.5M in private financing
https://seekingalpha.com/news/4091083-zura-bio-stock-jumps-on-plans-to-raise-1125m-in-private-financing?source=feed_sector_healthcare
Apr 18, 2024 - Zura Bio (ZURA) shares jumped around 12% after the immunology company entered into subscription agreements for a private placement.
0
Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade
https://www.zacks.com/stock/news/2263665/entera-bio-ltd-entx-stock-slides-as-market-rises-facts-to-know-before-you-trade?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2263665
Apr 26, 2024 - The latest trading day saw Entera Bio Ltd. (ENTX) settling at $1.98, representing a -1% change from its previous close.
0
Annovis Bio tumbles 53% on data for Alzheimer's candidate buntanetap
https://seekingalpha.com/news/4095540-annovis-bio-alzheimers-tumbles-53-data-alzheimers-candidate-buntanetap?source=feed_sector_healthcare
Apr 29, 2024 - Annovis Bio's Alzheimers disease candidate, buntanetap, triggers trading halts as shares fall ~53%, indicating potential disappointment in trial results. Read more here
0
Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question
https://seekingalpha.com/article/4688345-annovis-bio-alzheimer-phase-2-3-topline-readout-puts-buntanetap-future-into-question?source=feed_all_articles
May 01, 2024 - Annovis faces financial challenges and may see a significant decline in stock prices. Find out why ANVS stock is a Sell.
0
Bio-Rad Laboratories, Inc. (BIO) Q1 2024 Earnings Call Transcript
https://seekingalpha.com/article/4690550-bio-rad-laboratories-inc-bio-q1-2024-earnings-call-transcript?source=feed_sector_transcripts
May 07, 2024 - Bio-Rad Laboratories, Inc. (NYSE:NYSE:BIO) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ETCompany ParticipantsEdward Chung - Head, Investor...
0
Bluebird bio spikes even as CRISPR leads in gene therapy rollout
https://seekingalpha.com/news/4103984-bluebird-bio-stock-gains-q1-2024-results?source=feed_sector_healthcare
May 09, 2024 - Bluebird bio (BLUE) stock rises as Q1 financials exceed expectations despite lagging behind CRISPR Therapeutics (CRSP) in gene therapy rollout. Read more here.
0
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2271793/kronos-bio-inc-kron-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2271793
May 09, 2024 - Kronos Bio (KRON) delivered earnings and revenue surprises of -16.28% and 68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
0
GRI Bio files for $75M mixed shelf
https://seekingalpha.com/news/4104887-gri-bio-files-for-75m-mixed-shelf?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
May 10, 2024 - GRI Bio files a prospectus for a mixed shelf offering of up to $75M.
0
Tevogen Bio secures up to $50M in financing
https://seekingalpha.com/news/4104888-tevogen-bio-secures-up-to-50m-in-financing?source=feed_sector_healthcare
May 10, 2024 - Tevogen Bio secures up to $50M financing for research and development efforts, focused on clinical development of TVGN 489 from ExacTcell platform.
0
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2273125/generation-bio-co-gbio-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2273125
May 13, 2024 - Generation Bio (GBIO) delivered earnings and revenue surprises of -211.11% and 34.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
0